Trevi Therapeutics TRVI Stock
Trevi Therapeutics Price Chart
Trevi Therapeutics TRVI Financial and Trading Overview
| Trevi Therapeutics stock price | 15.9 USD |
| Previous Close | 15.91 USD |
| Open | 16.2 USD |
| Bid | 13.61 USD x 200 |
| Ask | 23.73 USD x 200 |
| Day's Range | 15.87 - 16.57 USD |
| 52 Week Range | 7.65 - 20.22 USD |
| Volume | 2.02M USD |
| Avg. Volume | 2.2M USD |
| Market Cap | 2.27B USD |
| Beta (5Y Monthly) | 1.046 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.18 USD |
TRVI Valuation Measures
| Enterprise Value | 1.95B USD |
| Trailing P/E | N/A |
| Forward P/E | -27.556324 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 7.0447497 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -32.792 |
Trading Information
Trevi Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.046 |
| 52-Week Change | 92.84% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 20.22 USD |
| 52 Week Low | 7.65 USD |
| 50-Day Moving Average | 17.85 USD |
| 200-Day Moving Average | 14.11 USD |
TRVI Share Statistics
| Avg. Volume (3 month) | 2.2M USD |
| Avg. Daily Volume (10-Days) | 1.34M USD |
| Shares Outstanding | 142.48M |
| Float | 118.32M |
| Short Ratio | 7.68 |
| % Held by Insiders | 0.62% |
| % Held by Institutions | 107.54% |
| Shares Short | 12.01M |
| Short % of Float | 9.35% |
| Short % of Shares Outstanding | 8.43% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.81% |
| Return on Equity (ttm) | -19.65% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -59420000 USD |
| Net Income Avi to Common (ttm) | -51107000 USD |
| Diluted EPS (ttm) | -0.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 318.87M USD |
| Total Cash Per Share (mrq) | 2.24 USD |
| Total Debt (mrq) | 605K USD |
| Total Debt/Equity (mrq) | 0.19 USD |
| Current Ratio (mrq) | 37.283 |
| Book Value Per Share (mrq) | 2.257 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -52629000 USD |
| Levered Free Cash Flow (ttm) | -33282124 USD |
Profile of Trevi Therapeutics
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 195 Church Street |
| ZIP | 06510 |
| Phone | 203 304 2499 |
| Website | https://www.trevitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 34 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Q&A For Trevi Therapeutics Stock
What is a current TRVI stock price?
Trevi Therapeutics TRVI stock price today per share is 15.9 USD.
How to purchase Trevi Therapeutics stock?
You can buy TRVI shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Trevi Therapeutics?
The stock symbol or ticker of Trevi Therapeutics is TRVI.
Which industry does the Trevi Therapeutics company belong to?
The Trevi Therapeutics industry is Biotechnology.
How many shares does Trevi Therapeutics have in circulation?
The max supply of Trevi Therapeutics shares is 142.48M.
What is Trevi Therapeutics Price to Earnings Ratio (PE Ratio)?
Trevi Therapeutics PE Ratio is now.
What was Trevi Therapeutics earnings per share over the trailing 12 months (TTM)?
Trevi Therapeutics EPS is -0.35 USD over the trailing 12 months.
Which sector does the Trevi Therapeutics company belong to?
The Trevi Therapeutics sector is Healthcare.
Trevi Therapeutics TRVI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2216.35 USD — |
+0.48
|
— — | 2215.68 USD — | 2236.57 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.07
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
- {{ link.label }} {{link}}
